Himani Devliyal is part of the Japan Delivery Center (JDC), Life Sciences, TCS. She has over 10 years of experience in various areas of pharmaceutical research and development, including pharmacovigilance, product quality claims management, compliance management and business development. She has worked as a scientist, pharmacovigilance manager and Argus expert in a professional capacity. She has also published research articles on new distribution systems of active substances (IUP formulation: in vitro and in vivo analysis). Himani graduated in pharmacology from Mr. Pharm. Deaths and life prognosis must be replaced in less than 7 calendar days. One of the main reasons for non-compliance with pharmacovigilance is the lack of SDEA. Routine monitoring of data exchanged in accordance with the SDEA is necessary. A database for SDEAs should be maintained for all products that list partners, agreement data, medicines covered, obligations and documents exchanged, etc. The incoming flow and management of this security information is governed by Security Data Exchange Agreements (SDEAs) and is prescribed by law in all cases where security data may be received by third parties, i.e.
not by the licensee. In order to prepare a Safety Data Exchange Agreement (SDEA), all aspects of regular and reliable cooperation with regard to pharmacovigilance obligations between the responsible parties should be taken into account and documented. The following points should be included in the SDEA: in addition, there must be a follow-up of companies that violate the agreements by sending late notifications or by not sending notifications at all. How to identify a company that is a remote site and does not send serious adverse events is another difficult topic and involves cooperation with the company`s quality and audit groups. The main objective of the pharmacovigilance agreement is to define a mechanism to ensure the flow of end-customer safety information to the competent authorities via the PDO. In order to ensure the achievement of this objective, it is the obligation of the POC to evaluate commercial contracts and to determine whether the clauses set out therein with regard to counterparties` commitments to photovoltaics are sufficient to carry out the activities. On the basis of that assessment, it is appropriate, where appropriate, to establish an autonomous agreement for which the period of validity of the last consignment marketed of the products concerned should be later than the date of validity. Nor should that period of effect take place at the end of the trade agreement concerned. All AEDSs must be part of the MAH quality management system and the letter, approval and documentation of each AEDS and any type of AEDS must comply with the company`s SOPs and be verifiable. This is a regulatory requirement and AEDS are inspected during pharmacovigilance inspections and audits. The legal department is the natural ally of drug safety for SDEAs.
It is obviously in the company`s interest to comply with laws and regulations in all markets, and the legal department is there for that. Problems often arise in this area, as these company agreements are concluded by research, distribution or commercial development groups, whose main objective is to launch studies or sell more medicines. Drug safety (adverse reaction reporting) is rarely at the top of their list of priorities. In fact, often they don`t even think about it or realize at the last minute that they need a security section. .